-
Mashup Score: 1
X-trodes Ltd. has received U.S. FDA 510(k) clearance for its Smart Skin solution, a wireless wearable technology that allows for medical-grade electrophysiological monitoring in clinics and at home. The company believes that the Smart Skin technology, which captures signals from the brain, heart, eyes and muscles, has the potential to significantly improve patient care.
Source: www.bioworld.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Grant supports Myrobalan’s development of CSF-1R inhibitor for ALS - 3 month(s) ago
Myrobalan Therapeutics Inc. has been awarded a $400,000 grant from the ALS Association to support the advancement of its colony-stimulating factor 1 receptor (CSF-1R) inhibitor for the treatment of amyotrophic lateral sclerosis (ALS).
Source: www.bioworld.comCategories: General Medicine News, Rare DiseaseTweet-
https://t.co/8G7ObKP24D
-
-
Mashup Score: 0UCHL1 associated with ALS progression, with impact on survival - 5 month(s) ago
University of Oxford scientists have presented data from deep proteomics of cerebrospinal fluid (CSF) in search of proteins with diagnostic or prognostic value in amyotrophic lateral sclerosis (ALS). Analysis was performed using CSF samples from 40 ALS patients, 15 controls (healthy individuals) and 8 mimicking conditions.
Source: www.bioworld.comCategories: General Medicine News, Rare DiseaseTweet-
https://t.co/vr8gPcdRFs
-
-
Mashup Score: 2
Harpoon Therapeutics Inc. provided updated interim monotherapy data from 71 patients in its phase I/II trial testing HPN-328 in small-cell lung cancer (SCLC) and other neuroendocrine tumor types in a poster at the European Society of Medical Oncology Congress (ESMO). Wall Street immediately began comparing the compound, which takes aim at delta-like ligand 3 (DLL3) with a similar prospect from Amgen Inc. that recently yielded promising results.
Source: www.bioworld.comCategories: General Medicine News, Hem/OncsTweet-
RT @BioWorld: .@HarpoonTx guns for SCLC penetration with DLL3 prospect as Amgen makes bigger #ESMO23 splash https://t.co/etL2mxi5MZ #biotec…
-
-
Mashup Score: 0| BioWorld - 12 month(s) ago
Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more
Source: www.bioworld.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Med-tech financings April 2023: #Venturecapital comprises 86% of declining #medtech financings in April | #IPO #VC #funding #medicaldevices https://t.co/ZX6GYyJPtc https://t.co/StW0OQCIu7
-
-
Mashup Score: 0
Gilde Healthcare Partners BV raised €600 million (US$658 million) in capital commitments for a new investment fund which will be deployed into companies across Europe and the U.S active in digital healthcare, medical technology and therapeutics. The fund, ‘Venture&Growth VI’, will focus on investing in fast growing companies developing solutions for better care at lower cost.
Source: www.bioworld.comCategories: Future of Medicine, Latest HeadlinesTweet-
Gilde Healthcare closes €600M fund for digital health, medtech and therapeutics https://t.co/qtt4odzjAk https://t.co/3x64iWm6Zh
-
-
Mashup Score: 1HIV cure, a less uncertain journey - 1 year(s) ago
HIV research is a winding road where one obstacle leads to another, slowing down success. The first barrier to getting the cure starts before one can even talk about it. “Cure may be too powerful and promising a term. Remission is probably better,” said John Mellors, whose work led to the universal use of plasma HIV-1 RNA and CD4+ T-cell counts in HIV-1 infection.“Cure means maintaining an…
Source: www.bioworld.comCategories: HIV/AIDS, Latest HeadlinesTweet-
In a new @BioWorld feature, IAS President @ProfSharonLewin and other experts examine recent developments in #HIV cure research and explore expectations for the coming years. https://t.co/BEqdoBtZ3m
-
-
Mashup Score: 0
Eikonoklastes Therapeutics Inc. and Forge Biologics Inc. have established a manufacturing partnership to advance Eikonoklastes’ adeno-associated viral (AAV)-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis (ALS).
Source: www.bioworld.comCategories: Latest Headlines, Rare DiseaseTweet-
AAV ET101 https://t.co/1elm2S8CVO
-
-
Mashup Score: 1
The companion diagnostic (CDx) has been a mainstay of oncology care for several years, but Richard Pazdur, director of the U.S. FDA’s Oncology Center of Excellence, said recently in a public forum recently that the notion of a single CDx for an investigational drug has not served patients well.
Source: www.bioworld.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @BioWorld: FDA divisions to develop pilot for companion diagnostic performance criteria https://t.co/c5AjkCehjl #biotech #pharma @FDAOnc…
-
-
Mashup Score: 0At EASD, insights into β-cell development and its discontents - 2 year(s) ago
Pancreatic β cells are the only cells in the body that produce insulin, and are the cells whose malfunctioning is the proximate cause of diabetes. Consequently, repairing or replacing β cells is one of the major goals of diabetes research. In type I diabetes, where the immune system destroys β cells, need to be replaced outright. In type II diabetes, β cells “disappear” in another way. There is…
Source: www.bioworld.comCategories: Future of Medicine, Latest HeadlinesTweet-
At EASD, insights into β-cell development and its discontents #NBTintheNews via @BioWorld https://t.co/ESyr1KBJYG
-
RT @BioWorldMedTech: X-trodes receives FDA clearance for Smart Skin electrophysiological system https://t.co/UDPKUcy7A2 #medtech @Xtrodes